Cargando…

Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients

BACKGROUND: Current standard therapy commonly followed for chronic Hepatitis C Virus (HCV) in Pakistan is interferon alpha plus ribavirin combination therapy (IFN α/ribavirin) and pegylated interferon plus ribavirin (PegIFN/ribavirin). PegIFN/ribavirin has increased rate of sustained virological res...

Descripción completa

Detalles Bibliográficos
Autores principales: Akram, Madiha, Idrees, Muhammad, Zafar, Shamail, Hussain, Abrar, Butt, Sadia, Afzal, Samia, Rehman, Irshad-ur, Liaqat, Ali, Saleem, Sana, Ali, Muhammad, Butt, Azeem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113307/
https://www.ncbi.nlm.nih.gov/pubmed/21575275
http://dx.doi.org/10.1186/1743-422X-8-234
_version_ 1782205919639109632
author Akram, Madiha
Idrees, Muhammad
Zafar, Shamail
Hussain, Abrar
Butt, Sadia
Afzal, Samia
Rehman, Irshad-ur
Liaqat, Ali
Saleem, Sana
Ali, Muhammad
Butt, Azeem
author_facet Akram, Madiha
Idrees, Muhammad
Zafar, Shamail
Hussain, Abrar
Butt, Sadia
Afzal, Samia
Rehman, Irshad-ur
Liaqat, Ali
Saleem, Sana
Ali, Muhammad
Butt, Azeem
author_sort Akram, Madiha
collection PubMed
description BACKGROUND: Current standard therapy commonly followed for chronic Hepatitis C Virus (HCV) in Pakistan is interferon alpha plus ribavirin combination therapy (IFN α/ribavirin) and pegylated interferon plus ribavirin (PegIFN/ribavirin). PegIFN/ribavirin has increased rate of sustained virological response than standard IFN α/ribavirin therapy. Objective of current study was to analyze rate of early and delayed response to antiviral treatment as well as rate of relapse response in patients following standard treatment IFN α/ribavirin and in patients following pegylated interferon treatment. METHODS: Baseline serum samples of 153 patients enrolled for IFN α/ribavirin and 50 patients for PegIFN/ribavirin were collected. After total RNA extraction, genotyping was and HCV RNA viral load was done. Subsequently HCV RNA viral load was estimated at 4 weeks of treatment, at 12 weeks, at 24 or 48 weeks and finally after 6 months follow up period. All the data was statistically analyzed using fisher's exact test. RESULTS: Total 86 patients out of 153 patients following conventional IFN α/ribavirin therapy completed treatment and 69% of them showed Rapid Virological Response (RVR). Whereas 50 patients following PegIFN/ribavirin treatment completed treatment and 80% of them achieved RVR. Total 64 out of 86 patients following IFN α/ribavirin therapy completed follow up period and 53.5% of them achieved Sustainded Virologcal Response (SVR). Forty-five out of total 50 patients who received PegIFN/ribavirin treatment completed 6 months follow up period and among these 70% achieved SVR. SVR rates were significantly associated with RVR (p < 0.001), age (p < 0.001) and gender (p < 0.01) CONCLUSIONS: Rate of sustained virological response can be determined by factors like rapid virological response and age since they share significant association with one another. More over rate of SVR was more prominent in males than in females.
format Online
Article
Text
id pubmed-3113307
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31133072011-06-14 Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients Akram, Madiha Idrees, Muhammad Zafar, Shamail Hussain, Abrar Butt, Sadia Afzal, Samia Rehman, Irshad-ur Liaqat, Ali Saleem, Sana Ali, Muhammad Butt, Azeem Virol J Research BACKGROUND: Current standard therapy commonly followed for chronic Hepatitis C Virus (HCV) in Pakistan is interferon alpha plus ribavirin combination therapy (IFN α/ribavirin) and pegylated interferon plus ribavirin (PegIFN/ribavirin). PegIFN/ribavirin has increased rate of sustained virological response than standard IFN α/ribavirin therapy. Objective of current study was to analyze rate of early and delayed response to antiviral treatment as well as rate of relapse response in patients following standard treatment IFN α/ribavirin and in patients following pegylated interferon treatment. METHODS: Baseline serum samples of 153 patients enrolled for IFN α/ribavirin and 50 patients for PegIFN/ribavirin were collected. After total RNA extraction, genotyping was and HCV RNA viral load was done. Subsequently HCV RNA viral load was estimated at 4 weeks of treatment, at 12 weeks, at 24 or 48 weeks and finally after 6 months follow up period. All the data was statistically analyzed using fisher's exact test. RESULTS: Total 86 patients out of 153 patients following conventional IFN α/ribavirin therapy completed treatment and 69% of them showed Rapid Virological Response (RVR). Whereas 50 patients following PegIFN/ribavirin treatment completed treatment and 80% of them achieved RVR. Total 64 out of 86 patients following IFN α/ribavirin therapy completed follow up period and 53.5% of them achieved Sustainded Virologcal Response (SVR). Forty-five out of total 50 patients who received PegIFN/ribavirin treatment completed 6 months follow up period and among these 70% achieved SVR. SVR rates were significantly associated with RVR (p < 0.001), age (p < 0.001) and gender (p < 0.01) CONCLUSIONS: Rate of sustained virological response can be determined by factors like rapid virological response and age since they share significant association with one another. More over rate of SVR was more prominent in males than in females. BioMed Central 2011-05-17 /pmc/articles/PMC3113307/ /pubmed/21575275 http://dx.doi.org/10.1186/1743-422X-8-234 Text en Copyright ©2011 Akram et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Akram, Madiha
Idrees, Muhammad
Zafar, Shamail
Hussain, Abrar
Butt, Sadia
Afzal, Samia
Rehman, Irshad-ur
Liaqat, Ali
Saleem, Sana
Ali, Muhammad
Butt, Azeem
Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
title Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
title_full Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
title_fullStr Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
title_full_unstemmed Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
title_short Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
title_sort effects of host and virus related factors on interferon-α+ribavirin and pegylated-interferon+ribavirin treatment outcomes in chronic hepatitis c patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113307/
https://www.ncbi.nlm.nih.gov/pubmed/21575275
http://dx.doi.org/10.1186/1743-422X-8-234
work_keys_str_mv AT akrammadiha effectsofhostandvirusrelatedfactorsoninterferonaribavirinandpegylatedinterferonribavirintreatmentoutcomesinchronichepatitiscpatients
AT idreesmuhammad effectsofhostandvirusrelatedfactorsoninterferonaribavirinandpegylatedinterferonribavirintreatmentoutcomesinchronichepatitiscpatients
AT zafarshamail effectsofhostandvirusrelatedfactorsoninterferonaribavirinandpegylatedinterferonribavirintreatmentoutcomesinchronichepatitiscpatients
AT hussainabrar effectsofhostandvirusrelatedfactorsoninterferonaribavirinandpegylatedinterferonribavirintreatmentoutcomesinchronichepatitiscpatients
AT buttsadia effectsofhostandvirusrelatedfactorsoninterferonaribavirinandpegylatedinterferonribavirintreatmentoutcomesinchronichepatitiscpatients
AT afzalsamia effectsofhostandvirusrelatedfactorsoninterferonaribavirinandpegylatedinterferonribavirintreatmentoutcomesinchronichepatitiscpatients
AT rehmanirshadur effectsofhostandvirusrelatedfactorsoninterferonaribavirinandpegylatedinterferonribavirintreatmentoutcomesinchronichepatitiscpatients
AT liaqatali effectsofhostandvirusrelatedfactorsoninterferonaribavirinandpegylatedinterferonribavirintreatmentoutcomesinchronichepatitiscpatients
AT saleemsana effectsofhostandvirusrelatedfactorsoninterferonaribavirinandpegylatedinterferonribavirintreatmentoutcomesinchronichepatitiscpatients
AT alimuhammad effectsofhostandvirusrelatedfactorsoninterferonaribavirinandpegylatedinterferonribavirintreatmentoutcomesinchronichepatitiscpatients
AT buttazeem effectsofhostandvirusrelatedfactorsoninterferonaribavirinandpegylatedinterferonribavirintreatmentoutcomesinchronichepatitiscpatients